Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab and Radiotherapy in Oligometastatic ES-SCLC
NCT05484583Phase 2Not yet recruiting
- Sponsor
- Cancer Center of Guangzhou Medical University
- Start
- Aug 2022
- Primary completion
- Aug 2024
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
01
Overview
A Phase 2 trial of durvalumab in small cell lung cancer (SCLC), sponsored by Cancer Center of Guangzhou Medical University. Planned start Aug 2022; status: not yet recruiting.
02
Drugs
durvalumab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT05484583.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05484583.